Abstract: The present disclosure relates to HIF-1? prolyl hydroxylase inhibitors, compositions which comprise the HIF-1? prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.
Type:
Grant
Filed:
August 20, 2010
Date of Patent:
January 1, 2013
Assignee:
Akebia Therapeutics Inc.
Inventors:
Shengde Wu, Namal C. Warshakoon, Artem G. Evdokimov, Kenneth D. Greis, Angelique Sun Boyer, Richard Masaru Kawamoto
Abstract: The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-?) inhibitors thereby regulating angiogenesis. The present disclosure further relates to compositions comprising one or more human protein tyrosine phosphatase beta (HPTP-?) inhibitors, and to methods for regulating angiogenesis.
Type:
Grant
Filed:
December 1, 2011
Date of Patent:
December 25, 2012
Assignee:
Aerpio Therapeutics Inc.
Inventors:
Jeffrey Lyle Gray, Kande K. D. Amarasinghe, Cynthia Monesa Clark, Ryan Matthew Nichols, Matthew B. Maier
Abstract: The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-?) inhibitors thereby regulating angiogenesis. The present disclosure further relates to compositions comprising said human protein tyrosine phosphatase beta (HPTP-?) inhibitors, and to methods for regulating angiogenesis.
Type:
Grant
Filed:
December 1, 2011
Date of Patent:
December 11, 2012
Assignee:
Aerpio Therapeutics Inc.
Inventors:
Kande K. D. Amarasinghe, Cynthia Monesa Clark, Ryan Matthew Nichols, Matthew B. Maier, Jeffrey Lyle Gray
Abstract: The present disclosure relates to HIF-1? prolyl hydroxylase inhibitors, compositions which comprise the HIF-1? prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.
Type:
Grant
Filed:
August 20, 2010
Date of Patent:
December 4, 2012
Assignee:
Akebia Therapeutics Inc.
Inventors:
Shengde Wu, Namal C. Warshakoon, Artem G. Evdokimov, Kenneth D. Greis, Angelique Sun Boyer, Richard Masaru Kawamoto
Abstract: Disclosed are compositions, inter alia, shampoos, conditioners, and restoratives that are effective in preventing further damage to keratin-containing fibers damaged by exposure to oxidative dyeing catalysts, mechanical damage, exposure to UV and visible radiation, and the like.
Type:
Grant
Filed:
September 2, 2010
Date of Patent:
November 27, 2012
Assignee:
Kelly Van Gogh Hair Colour Cosmetics, Inc.
Abstract: Disclosed herein are compositions and methods for treating colitis and other inflammatory bowel diseases, inter alia, indeterminate colitis, Crohn's disease, irritable bowel syndrome and ischemic colitis.
Abstract: The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-?) inhibitors thereby regulating angiogenesis. The present disclosure further relates to compositions comprising said human protein tyrosine phosphatase beta (HPTP-?) inhibitors, and to methods for regulating angiogenesis.
Type:
Grant
Filed:
November 23, 2009
Date of Patent:
September 4, 2012
Assignee:
Aerpio Therapeutics Inc.
Inventors:
Jeffrey Lyle Gray, Kande K. D. Amarasinghe, Cynthia Monesa Clark, Ryan Matthew Nichols, Matthew B. Maier
Abstract: Disclosed herein are compositions suitable for use in dyeing keratin-containing fibers. Further disclosed herein are colorant systems and compositions comprising the colorant systems. Also disclosed are kits comprising one or more colorant systems and an activator composition.
Abstract: The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-?) inhibitors thereby regulating angiogenesis. The present disclosure further relates to compositions comprising one or more human protein tyrosine phosphatase beta (HPTP-?) inhibitors, and to methods for regulating angiogenesis.
Type:
Grant
Filed:
May 18, 2009
Date of Patent:
May 29, 2012
Assignee:
Aerpio Therapeutics Inc.
Inventors:
Jeffrey Lyle Gray, Kande K. D. Amarasinghe, Cynthia Monesa Clark, Ryan Matthew Nichols, Matthew B. Maier
Abstract: The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-?) inhibitors thereby regulating angiogenesis. The present disclosure further relates to compositions comprising said human protein tyrosine phosphatase beta (HPTP-?) inhibitors, and to methods for regulating angiogenesis.
Type:
Grant
Filed:
August 4, 2010
Date of Patent:
January 31, 2012
Assignee:
Warner Chilcott Company, LLC
Inventors:
Jeffrey Lyle Gray, Kande K. D. Amarasinghe, Cynthia Monesa Clark, Ryan Matthew Nichols, Matthew B. Maier
Abstract: Disclosed herein are compositions suitable for use in dyeing keratin-containing fibers. Further disclosed herein are colorant systems and compositions comprising the colorant systems. Also disclosed are kits comprising one or more colorant systems and an activator composition.
Abstract: The crystal structure of ligand-bound EGLN1 catalytic domain of prolyl hydroxylase is disclosed. These coordinates are useful in computer aided drug design for identifying compounds that regulate EGLN1 prolyl hydroxylase and thereby regulate HIF-regulated disorders.
Type:
Grant
Filed:
May 28, 2009
Date of Patent:
November 1, 2011
Assignee:
Warner Chilcott Company
Inventors:
Artem Gennady Evdokimov, Richard Masaru Kawamoto, Angelique Sun Boyer, Marlene Jan Mekel, Matthew Eugene Pokross, Richard Lee Walter, Jr.
Abstract: The present disclosure relates to HIF-1? prolyl hydroxylase inhibitors, compositions which comprise the HIF-1? prolyl hydroxylase inhibitors described herein and to methods for controlling, inter alia, Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, and anemia.
Type:
Grant
Filed:
June 26, 2007
Date of Patent:
October 12, 2010
Assignee:
Warner Chilcott Company, LLC
Inventors:
Richard Masaru Kawamoto, Shengde Wu, Namal C. Warshakoon, Artem G. Evdokimov, Kenneth D. Greis, Angelique Sun Boyer
Abstract: The present disclosure relates to compounds effective as human protein tyrosine phosphatase beta (HPTP-?) inhibitors thereby regulating angiogenesis. The present disclosure further relates to compositions comprising said human protein tyrosine phosphatase beta (HPTP-?) inhibitors, and to methods for regulating angiogenesis.
Type:
Grant
Filed:
June 26, 2007
Date of Patent:
September 14, 2010
Assignee:
Warner Chilcott Company
Inventors:
Jeffrey Lyle Gray, Kande K. D. Amarasinghe, Cynthia Monesa Clark, Ryan Matthew Nichols, Matthew B. Maier
Abstract: The crystal structures of catalytic domain of HPTPbeta, both ligand-bound and ligand-free are described. These structures are useful in computer aided drug design for identifying compounds that bind or activate HPTPbeta and thereby modulate angiogenesis mediated disorders or diseases.
Type:
Grant
Filed:
March 23, 2009
Date of Patent:
August 3, 2010
Assignee:
Warner Chilcott, LLC
Inventors:
Artem Gennady Evdokimov, Matthew Eugene Pokross
Abstract: The present invention relates to novel compounds, compositions comprising said compounds, and uses thereof, said compounds having the formula: X is —CH2—, —O— or —NR9—; R is a carbocyclic or heterocyclic ring; R1 is a cysteine trap; R2a, R2a?, R2b, and R2b? are each independently hydrogen, C1–C4 alkyl, C1–C4 alkoxy, and mixtures thereof; or R2a? and R2b? can taken together to form a double bond; R9 is hydrogen or a unit having the formula -L2-R10; L is the same as defined herein above; R10 is hydrogen; substituted or unsubstituted C1–C6 linear; branched, or cyclic hydrocarbyl; substituted or unsubstituted aryl; substituted or unsubstituted C1–C9 heterocyclic; and substituted or unsubstituted heteroaryl.
Type:
Grant
Filed:
June 9, 2003
Date of Patent:
November 21, 2006
Assignee:
The Procter & Gamble Company
Inventors:
Steven Victor O'Neil, Michael Christopher Laufersweiler, Yili Wang, Kofi Abeka Oppong, David Lindsey Soper, John August Wos, Biswanath De, Thomas Prosser Demuth, Jr.